SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1050 participants.
Also called NCT07105917
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,050 participants
- Registry
-
NCT07105917
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07105917. Randomized; single masking; primary purpose treatment. Start 2025-08-01 (anticipated); primary completion 2026-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- SGLT-2 inhibitors
- Intervention (Other)
- Standard medical treatment
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct07105917- Content hash
90bd71af8c8cdfc5df07b7c95032e65aa5f41b1953505d8be69db871daa2bc2b